Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Many neurodegenerative diseases, including Alzheimer's and Parkinson's and the transmissible spongiform encephalopathies (prion diseases), are characterized at autopsy by neuronal loss and protein aggregates that are typically fibrillar. A convergence of evidence strongly suggests that protein aggregation is neurotoxic and not a product of cell death. However, the identity of the neurotoxic aggregate and the mechanism by which it disables and eventually kills a neuron are unknown. Both biophysical studies aimed at elucidating the precise mechanism of in vitro aggregation and animal modeling studies support the emerging notion that an ordered prefibrillar oligomer, or protofibril, may be responsible for cell death and that the fibrillar form that is typically observed at autopsy may actually be neuroprotective. A subpopulation of protofibrils may function as pathogenic amyloid pores. An analogous mechanism may explain the neurotoxicity of the prion protein; recent data demonstrates that the disease-associated, infectious form of the prion protein differs from the neurotoxic species. This review focuses on recent experimental studies aimed at identification and characterization of the neurotoxic protein aggregates.

[1]  S. Prusiner,et al.  Scrapie prions aggregate to form amyloid-like birefringent rods , 1983, Cell.

[2]  H. Gelderblom,et al.  Scrapie infectivity, fibrils and low molecular weight protein , 1983, Nature.

[3]  L. Kurland,et al.  Fine Structural Study of Neurofibrillary Changes in a Family with Amyotrophic Lateral Sclerosis , 1984, Journal of neuropathology and experimental neurology.

[4]  Ruedi Aebersold,et al.  A cellular gene encodes scrapie PrP 27-30 protein , 1985, Cell.

[5]  G. Multhaup,et al.  The major polypeptide of scrapie‐associated fibrils (SAF) has the same size, charge distribution and N‐terminal protein sequence as predicted for the normal brain protein (PrP). , 1986, The EMBO journal.

[6]  S. Prusiner,et al.  Properties of scrapie prion protein liposomes. , 1988, The Journal of biological chemistry.

[7]  G. Multhaup,et al.  Molecular pathology of scrapie-associated fibril protein (PrP) in mouse brain affected by the ME7 strain of scrapie. , 1988, European Journal of Biochemistry.

[8]  L. Hood,et al.  Purification and properties of the cellular and scrapie hamster prion proteins. , 1988, European journal of biochemistry.

[9]  P. McBride,et al.  Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie , 1989, Neuroscience Letters.

[10]  P. Liberski,et al.  Conservation of infectivity in purified fibrillary extracts of scrapie-infected hamster brain after sequential enzymatic digestion or polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[12]  D. Zopf,et al.  Molecular mass, biochemical composition, and physicochemical behavior of the infectious form of the scrapie precursor protein monomer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. J. Raymond,et al.  The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. , 1991, The Journal of biological chemistry.

[14]  G. J. Raymond,et al.  N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state , 1991, Journal of virology.

[15]  S. Prusiner,et al.  Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis , 1991, Journal of virology.

[16]  S. Prusiner,et al.  Evidence for synthesis of scrapie prion proteins in the endocytic pathway. , 1992, The Journal of biological chemistry.

[17]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[18]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[19]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[20]  R. Bowler,et al.  Three scrapie prion isolates exhibit different accumulation patterns of the prion protein scrapie isoform. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[22]  E. Rojas,et al.  Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Ushijima,et al.  Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. , 1993, European journal of pharmacology.

[24]  P. Lansbury,et al.  Cell-free formation of protease-resistant prion protein , 1994, Nature.

[25]  J. Hope The Nature of the Scrapie Agent: The Evolution of the Virino , 1994, Annals of the New York Academy of Sciences.

[26]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Prusiner,et al.  Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins , 1994, Cell.

[28]  T. Umahara,et al.  Cu Zn superoxide dismutase-like immunoreactivity in Lewy body-like inclusions of sporadic amyotrophic lateral sclerosis , 1994, Neuroscience Letters.

[29]  S. Prusiner,et al.  Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Borchelt,et al.  Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[32]  P. Andersen,et al.  Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase , 1995, Nature Genetics.

[33]  W. Hung,et al.  Intense Superoxide Dismutase‐1 Immunoreactivity in Intracytoplasmic Hyaline Inclusions of Familial Amyotrophic Lateral Sclerosis with Posterior Column Involvement , 1996, Journal of neuropathology and experimental neurology.

[34]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[35]  S. Prusiner,et al.  Disruption of prion rods generates 10-nm spherical particles having high alpha-helical content and lacking scrapie infectivity , 1996, Journal of virology.

[36]  R. Kastelein,et al.  Mouse T Cell Membrane Proteins Rt61 and Rt62 Are Arginine/Protein Mono(ADPribosyl)transferases and Share Secondary Structure Motifs with ADP-ribosylating Bacterial Toxins (*) , 1996, The Journal of Biological Chemistry.

[37]  E. Rojas,et al.  Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Selkoe,et al.  Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation , 1996, Neurobiology of Disease.

[39]  W. Robberecht,et al.  D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis , 1996, Neurology.

[40]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[41]  N. Shibata,et al.  Sporadic amyotrophic lateral sclerosis with dementia and Cu/Zn superoxide dismutase-positive Lewy body-like inclusions. , 1996, Clinical neuropathology.

[42]  A. Aguzzi,et al.  Normal host prion protein necessary for scrapie-induced neurotoxicity , 1996, Nature.

[43]  M. Eigen,et al.  Prionics or the kinetic basis of prion diseases. , 1996, Biophysical chemistry.

[44]  F. Cohen,et al.  High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. , 1996, Biochemistry.

[45]  R. Petersen,et al.  Effect of the D178N Mutation and the Codon 129 Polymorphism on the Metabolism of the Prion Protein (*) , 1996, The Journal of Biological Chemistry.

[46]  Guy A. Rouleau,et al.  SOD1 mutation is assosiated with accumulation of neurofilaments in amyotrophic lateral scelaries , 1996 .

[47]  F. Cohen,et al.  Physical studies of conformational plasticity in a recombinant prion protein. , 1997, Biochemistry.

[48]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[49]  B. Kagan,et al.  Channel Formation by a Neurotoxic Prion Protein Fragment* , 1997, The Journal of Biological Chemistry.

[50]  J. Rossier,et al.  Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein , 1997, Science.

[51]  Peter T. Lansbury,et al.  Observation of metastable Aβ amyloid protofibrils by atomic force microscopy , 1997 .

[52]  P. Lansbury,et al.  Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. , 1997, Chemistry & biology.

[53]  Shu G. Chen,et al.  Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation* , 1997, The Journal of Biological Chemistry.

[54]  D. Figlewicz,et al.  Aggregation of Mutant Cu/Zn Superoxide Dismutase Proteins in a Culture Model of ALS , 1997, Journal of neuropathology and experimental neurology.

[55]  G. J. Raymond,et al.  In Situ Formation of Protease-resistant Prion Protein in Transmissible Spongiform Encephalopathy-infected Brain Slices* , 1997, The Journal of Biological Chemistry.

[56]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[57]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[58]  Robert H. Brown,et al.  Amyotrophic lateral sclerosis. Insights from genetics. , 1997, Archives of neurology.

[59]  P. Andersen,et al.  Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. , 1997, Brain : a journal of neurology.

[60]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[61]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[62]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[63]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.

[64]  P. Lansbury,et al.  A detergent-insoluble membrance compartment contains Aβ in vivo , 1998, Nature Medicine.

[65]  A. Paetau,et al.  A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1 , 1998, Nature Medicine.

[66]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[67]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[68]  C. Hayward,et al.  Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. , 1998, Journal of medical genetics.

[69]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  B. Caughey,et al.  The importance of the disulfide bond in prion protein conversion , 1998, Neuroreport.

[71]  A. Giese,et al.  Role of Microglia in Neuronal Cell Death in Prion Disease , 1998, Brain pathology.

[72]  D. Cleveland From Charcot to SOD1 Mechanisms of Selective Motor Neuron Death in ALS , 1999, Neuron.

[73]  J. Collinge,et al.  Protease-resistant prion protein produced in vitro lacks detectable infectivity. , 1999, The Journal of general virology.

[74]  C. Dobson Protein misfolding, evolution and disease. , 1999, Trends in biochemical sciences.

[75]  C. Soto,et al.  Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. , 1999, Biochemical and biophysical research communications.

[76]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[77]  J Collinge,et al.  Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. , 1999, Science.

[78]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[79]  Peter T. Lansbury,et al.  Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .

[80]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[81]  V. Daggett,et al.  PrPc glycoform heterogeneity as a function of brain region: implications for selective targeting of neurons by prion strains. , 1999, Journal of neuropathology and experimental neurology.

[82]  P. Lansbury Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Selkoe,et al.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. , 1999, The Journal of biological chemistry.

[84]  R. Glockshuber,et al.  Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. , 1999, Biochemistry.

[85]  B. Caughey,et al.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease‐resistant state , 1999, The EMBO journal.

[86]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[87]  G A Johnson,et al.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[88]  S. Prusiner,et al.  Transmissible and genetic prion diseases share a common pathway of neurodegeneration , 1999, Nature.

[89]  M. Citron,et al.  alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.

[90]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[91]  P. Lansbury,et al.  Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.

[92]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[93]  T. Wisniewski,et al.  Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.

[94]  D. Westaway,et al.  Copper(II)-induced Conformational Changes and Protease Resistance in Recombinant and Cellular PrP , 2000, The Journal of Biological Chemistry.

[95]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[96]  D. Riesner,et al.  Neurotoxicity but not infectivity of prion proteins can be induced reversibly in vitro. , 2000, Archives of virology. Supplementum.

[97]  A. Paetau,et al.  Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS‐1 mutations that lead to exceptionally high amyloid‐β concentrations , 2000, Annals of neurology.

[98]  F E Cohen,et al.  A synthetic peptide initiates Gerstmann-Sträussler-Scheinker (GSS) disease in transgenic mice. , 2000, Journal of molecular biology.

[99]  A. Johnston,et al.  Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie‐infected murine hippocampus , 2000, Neuropathology and applied neurobiology.

[100]  Kenji Nakashima,et al.  New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: Inclusions containing SOD1 in neurons and astrocytes , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[101]  M. Gurney,et al.  Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[103]  D. F. Andrews,et al.  A one-hit model of cell death in inherited neuronal degenerations , 2000, Nature.

[104]  D. Cleveland,et al.  Oxidation versus aggregation — how do SOD1 mutants cause ALS? , 2000, Nature Medicine.

[105]  D. Selkoe,et al.  A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils , 2000, Nature Structural Biology.

[106]  P N Leigh,et al.  Recent advances in amyotrophic lateral sclerosis , 2000, Current opinion in neurology.

[107]  J. Julien,et al.  The neuronal Golgi apparatus is fragmented in transgenic mice expressing a mutant human SOD1, but not in mice expressing the human NF-H gene , 2000, Journal of the Neurological Sciences.

[108]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[109]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[110]  B. Ghetti,et al.  Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  J. Bureš,et al.  Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  R. S. Stewart,et al.  Most Pathogenic Mutations Do Not Alter the Membrane Topology of the Prion Protein* , 2001, The Journal of Biological Chemistry.

[113]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[114]  M. Baldwin Mass spectrometric analysis of prion proteins. , 2001, Advances in protein chemistry.

[115]  J. Julien,et al.  Amyotrophic Lateral Sclerosis Unfolding the Toxicity of the Misfolded , 2001, Cell.

[116]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[117]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[118]  W. Surewicz,et al.  On the Mechanism of α-Helix to β-Sheet Transition in the Recombinant Prion Protein† , 2001 .

[119]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[120]  M. Kirkitadze,et al.  Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. , 2001, Journal of molecular biology.

[121]  C. Haass,et al.  Protofibrils, the unifying toxic molecule of neurodegenerative disorders? , 2001, Nature Neuroscience.

[122]  D. Dickson,et al.  Analysis of tauopathies with transgenic mice. , 2001, Trends in molecular medicine.

[123]  Rushana Azimova,et al.  The channel hypothesis of Huntington’s disease , 2001, Brain Research Bulletin.

[124]  B. Austen,et al.  Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. , 2001, Journal of Molecular Biology.

[125]  M. F. Perutz,et al.  Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats , 2001, Nature.

[126]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[127]  G. Rouleau,et al.  Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family , 2001, Annals of neurology.

[128]  G. Forloni,et al.  Studies on peptide fragments of prion proteins. , 2001, Advances in protein chemistry.

[129]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[130]  K Wüthrich,et al.  Three-dimensional structures of prion proteins. , 2001, Advances in protein chemistry.

[131]  H. Scheraga,et al.  A role for intermolecular disulfide bonds in prion diseases? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[132]  Witold K. Surewicz,et al.  Crystal structure of the human prion protein reveals a mechanism for oligomerization , 2002, Nature Structural Biology.

[133]  B. Caughey,et al.  Reversibility of Scrapie-associated Prion Protein Aggregation* , 2001, The Journal of Biological Chemistry.

[134]  D. Harris,et al.  Copper Converts the Cellular Prion Protein into a Protease-resistant Species That Is Distinct from the Scrapie Isoform* , 2001, The Journal of Biological Chemistry.

[135]  Y. Cordeiro,et al.  DNA Converts Cellular Prion Protein into the β-Sheet Conformation and Inhibits Prion Peptide Aggregation* , 2001, The Journal of Biological Chemistry.

[136]  A. Chong,et al.  Onset of accumulation of PrPres in murine ME7 scrapie in relation to pathological and PrP immunohistochemical changes. , 2001, Journal of comparative pathology.

[137]  D. Harris Biosynthesis and cellular processing of the prion protein. , 2001, Advances in protein chemistry.

[138]  S. Minotti,et al.  Mutant Cu/Zn-Superoxide Dismutase Proteins Have Altered Solubility and Interact with Heat Shock/Stress Proteins in Models of Amyotrophic Lateral Sclerosis* , 2001, The Journal of Biological Chemistry.

[139]  S. Prusiner,et al.  Copper-catalyzed oxidation of the recombinant SHa(29–231) prion protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[140]  B. Permanne,et al.  Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding , 2001, Nature.

[141]  J. Hardy,et al.  A Pathogenic Presenilin-1 Deletion Causes Abberrant Aβ42 Production in the Absence of Congophilic Amyloid Plaques* , 2001, The Journal of Biological Chemistry.

[142]  D. Small,et al.  Alzheimer's disease and Aβ toxicity: from top to bottom , 2001, Nature Reviews Neuroscience.

[143]  T. Morgan,et al.  Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.

[144]  R. Glockshuber Folding dynamics and energetics of recombinant prion proteins. , 2001, Advances in protein chemistry.

[145]  G. J. Raymond,et al.  Interactions and conversions of prion protein isoforms. , 2001, Advances in protein chemistry.

[146]  R. Lal,et al.  Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[147]  B. Caughey,et al.  Interactions between prion protein isoforms: the kiss of death? , 2001, Trends in biochemical sciences.

[148]  G. J. Raymond,et al.  Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein , 2001, Journal of neurochemistry.

[149]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[150]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[151]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[152]  B. Chesebro,et al.  Conversion of raft associated prion protein to the protease‐resistant state requires insertion of PrP‐res (PrPSc) into contiguous membranes , 2002, The EMBO journal.

[153]  M. Beal,et al.  Mutated Human SOD1 Causes Dysfunction of Oxidative Phosphorylation in Mitochondria of Transgenic Mice* , 2002, The Journal of Biological Chemistry.

[154]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[155]  A. Chakrabartty,et al.  Oxidation-induced Misfolding and Aggregation of Superoxide Dismutase and Its Implications for Amyotrophic Lateral Sclerosis* , 2002, The Journal of Biological Chemistry.

[156]  S. Lindquist,et al.  Neurotoxicity and Neurodegeneration When PrP Accumulates in the Cytosol , 2002, Science.

[157]  I. Vorberg,et al.  Molecular Basis of Scrapie Strain Glycoform Variation* , 2002, The Journal of Biological Chemistry.

[158]  N. Arispe,et al.  Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AβP (1–40) and (1–42) peptides , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[159]  H. Cai,et al.  Genetically engineered mouse models of neurodegenerative diseases , 2002, Nature Neuroscience.

[160]  Seung-Jae Lee,et al.  Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. , 2002, The Journal of biological chemistry.

[161]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[162]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[163]  Christopher A Ross,et al.  Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.

[164]  C. Dobson,et al.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.

[165]  Robert H. Brown,et al.  Familial Amyotrophic Lateral Sclerosis-associated Mutations Decrease the Thermal Stability of Distinctly Metallated Species of Human Copper/Zinc Superoxide Dismutase* , 2002, The Journal of Biological Chemistry.

[166]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[167]  David A Agard,et al.  Structural studies of the scrapie prion protein by electron crystallography , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[168]  T. Pinheiro,et al.  Binding of prion protein to lipid membranes and implications for prion conversion. , 2002, Journal of molecular biology.

[169]  Peter T Lansbury,et al.  Genetics of Parkinson's disease and biochemical studies of implicated gene products. , 2002, Current opinion in cell biology.

[170]  Patrik Brundin,et al.  Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. , 2002, Human molecular genetics.

[171]  Christopher A. Ross,et al.  Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.

[172]  J. Hoh,et al.  Growth of β-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy , 2002 .

[173]  Neena Singh,et al.  Prion Peptide 106–126 Modulates the Aggregation of Cellular Prion Protein and Induces the Synthesis of Potentially Neurotoxic Transmembrane PrP* , 2002, The Journal of Biological Chemistry.

[174]  Christina A. Wilson,et al.  Presenilins are not required for Aβ42 production in the early secretory pathway , 2002, Nature Neuroscience.

[175]  F. Hartl,et al.  Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein , 2002, Science.

[176]  Rustam Azimov,et al.  The channel hypothesis of Alzheimer’s disease: current status , 2002, Peptides.

[177]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[178]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[179]  D. Borchelt,et al.  Fibrillar Inclusions and Motor Neuron Degeneration in Transgenic Mice Expressing Superoxide Dismutase 1 with a Disrupted Copper-Binding Site , 2002, Neurobiology of Disease.

[180]  F. Cohen,et al.  Pathway Complexity of Prion Protein Assembly into Amyloid* , 2002, The Journal of Biological Chemistry.

[181]  P. Lansbury,et al.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.

[182]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[183]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[184]  H. E. Stanley,et al.  Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[185]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[186]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[187]  A. LeBlanc,et al.  Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons , 2002, The Journal of cell biology.

[188]  J. Schaack,et al.  Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture , 2002, Brain Research.

[189]  H. Scheraga,et al.  Intramolecular Versus Intermolecular Disulfide Bonds in Prion Proteins* , 2002, The Journal of Biological Chemistry.

[190]  Robert H. Brown,et al.  Decreased Metallation and Activity in Subsets of Mutant Superoxide Dismutases Associated with Familial Amyotrophic Lateral Sclerosis* 210 , 2002, The Journal of Biological Chemistry.

[191]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[192]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[193]  K. Fischbeck,et al.  Toxic Proteins in Neurodegenerative Disease , 2002, Science.

[194]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[195]  S. Lindquist,et al.  Conversion of PrP to a Self-Perpetuating PrPSc-like Conformation in the Cytosol , 2002, Science.

[196]  H. Wiśniewski,et al.  Abnormal fibrils from scrapie-infected brain , 2004, Acta Neuropathologica.